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Abstract
Introduction: Oncocytomas of adrenal glands are extremely rare and usually present as incidentally detected masses. We aimed to present 
a series of patients with adrenal oncocytomas and review the literature.
Material and methods: Electronic database of patients with adrenal tumours, who were admitted to the internal medicine and endo-
crinology and metabolism outpatient clinics of Uludag University Medical Faculty between January 2005 and November 2016, were 
assessed retrospectively. Those who underwent surgery and pathological diagnosis of oncocytoma (n = 11) were included to the study. 
The demographic, clinical, pathological, radiological, and laboratory features were evaluated.
Results: Of these 11 patients, 54.5% (n = 6) were female and 45.5% (n = 5) were male. They aged between 31 and 76 years (45.36 ± 13.68). 
Five (45.5%) of the masses showed endocrinological activity and were more frequent in women. The masses were 25–130 (57.63 ± 34.04) 
mm in width and 20–100 (47.82 ± 28.95) mm in length. Seven (63.6%) oncocytomas were classified as benign and the remainder as hav-
ing uncertain malignant potential according to Lin-Weiss-Bisceglia criteria. Mean duration of follow-up were 24.8 (6–60) months and 38.2 
(15–82) months, respectively.
Conclusions: Because there are no unique clinical and imaging characteristics differentiating adrenal oncocytomas from other types 
of adrenal masses, it should be kept in mind in differential diagnosis of adrenal masses, especially large ones and those suspicious for 
adrenocortical carcinoma. (Endokrynol Pol 2018; 69 (6): 682–687)
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Streszczenie
Wstęp: Onkocytoma nadnerczy to niezwykle rzadki nowotwór, zwykle wykrywany przypadkowo. Autorzy przedstawiają serię 11 przy-
padków chorych z guzem onkocytarnym nadnerczy oraz przegląd piśmiennictwa.
Materiał i metody: Oceniono retrospektywnie elektroniczną bazę danych pacjentów z guzami nadnerczy przyjętych do Kliniki Chorób 
Wewnętrznych oraz Kliniki Endokrynologicznej i Zaburzeń Metabolicznych Wydziału Medycznego Uniwersytetu w Uludag w okresie od 
stycznia 2005 do listopada 2016 roku. Do badania włączono osoby, u których wykonano zabieg chirurgiczny i na podstawie badania histopa-
tologicznego rozpoznano onkocytoma (n = 11). Przeanalizowano dane demograficzne, kliniczne, patologiczne, radiologiczne i laboratoryjne.
Wyniki: Spośród tych 11 chorych kobiety stanowiły 54,5% (n = 6), a mężczyźni 45,5% (n = 5). Badani byli w wieku 31–76 lat (45,36 ± 13,68). 
Aktywność hormonalną stwierdzono w przypadku 5 guzów (45,5%), hormonalnie czynne guzy występowały częściej u kobiet. Wymiary 
guzów wynosiły: szerokość — 25–130 mm (57,63 ± 34,04 mm) i długość — 20–100 mm (47,82 ± 28,95 mm). Siedem guzów onkocytarnych 
(63,6%) sklasyfikowano jako łagodne, a pozostałe jako guzy o niepewnym potencjale złośliwości na podstawie kryteriów klasyfikacji 
Lin-Weiss-Bisceglia. Średni czas obserwacji wynosił odpowiednio 24,8 miesiąca (6–60 mies.) i 38,2 miesiąca (15–82 mies.).
Wnioski: Z uwagi na to, że nie ma szczególnych objawów klinicznych ani cech w badaniach obrazowych odróżniających nowotwory 
onkocytarne od innych guzów nadnerczy, należy pamiętać o tych guzach podczas diagnozy różnicowej masy wykrytej w nadnerczach, 
zwłaszcza jeśli jest ona duża i budzi podejrzenie raka kory nadnerczy. (Endokrynol Pol 2018; 69 (6): 682–687)
Słowa kluczowe: incidentaloma nadnerczy; onkocytoma nadnerczy; zespół Cushinga; zespół Conna; niepewny stopień złośliwości
Introduction
An adrenal mass that is detected incidentally on 
radiological evaluation of a patient without signs or 
symptoms attributable to adrenal disease is defined 
as an “adrenal incidentaloma”. Most of the cases are 
non-functional adrenocortical adenomas. Adrenocorti-
cal carcinomas, cysts, ganglioneuromas, myelolipomas, 
haematomas, pheochromocytomas, and adrenal me-
tastases are the other possible causes [1]. Oncocytoma 
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used for histological subtype (9). Duration of follow-up 
was also noted.
Biochemical and hormonal assessment
Biochemical and endocrinological assessment included 
the following:
 — serum fasting blood glucose, urea, creatinine, so-
dium, alanine aminotransferase, aspartate amino-
transferase, complete blood count;
 — serum adrenocorticotropic hormone (ACTH) and 
cortisol levels were measured at 08:00 a.m.;
 — measurements of adrenaline, noradrenaline, meta-
nephrine, normetanephrine, dopamine, and vanil-
lylmandelic acid in 24-hour collected urine (one or 
more of them);
 — plasma renin activity (PRA) and serum aldosterone 
level only in patients with hypertension;
 — serum cortisol level after 1 mg dexamethasone 
suppression test (DST) (1 mg dexamethasone was 
administered via oral route at 23:00 p.m., and fasting 
serum samples were collected at 08:00 a.m.);
 — 2 mg DST for two days in patients with serum corti-
sol levels not suppressed below 1.8 µg/dl after 1 mg 
DST (dexamethasone 0.5 mg tablet was given orally 
every six hours for two consecutive days and serum 
samples were collected at 08:00 a.m.);
 — midnight serum cortisol level at 23:00 p.m.;
 — cortisol measurement in 24-hour collected urine.
The patients with cortisol levels not suppressed below 
1.8 µg/dL (50 nmol/L) during 1 and 2 mg DST, impaired di-
urnal rhythm, and low morning ACTH level without clin-
ical manifestations of Cushing syndrome (CS) were con-
sidered to have subclinical CS. Patients with PRA less than 
1 ng/mL/hour, plasma aldosterone level over 15 ng/dL, 
and renin activity/aldosterone ratio (RAO) over 20 were 
further tested for hyperaldosteronism.
Statistical analysis
Statistical analysis was made using computer soft-
ware SPSS version 16.0 (SPSS Inc. Chicago, IL, USA). 
Categorical variables were expressed as number and 
percentage (%) and continuous variables were ex-
pressed as mean (± standard deviation) and median 
(minimum–maximum).
Results
Out of 11 patients, 54.5% (n:6) were female and 45.5% 
(n: 5) were male. The patients were aged between 31 
and 76 (45.36 ± 13.68) years. The mean ages of the 
female and male patients were 48.50 ± 16.86 and 
41.60 ± 8.96 years, respectively. The masses were mostly 
detected during radiological investigation for vague 
abdominal pain, urological problems, or pulmonary 
is a rare aetiology of adrenal incidentaloma. The term 
“oncocyte” was first used by Hamperl to describe large 
granular cells with eosinophilic cytoplasm observed in 
Hurthle cell tumours of the thyroid gland [2]. In 1986, 
Kakimoto et al. reported a mass in the adrenal gland 
with a similar appearance to oncocytoma; however, the 
tumour was termed as adrenocortical adenoma due 
to lack of clear definition of adrenal oncocytoma (AO) 
[3]. In the same year, after confirmation by electron mi-
croscopy by Smirnova et al. [4], the term AO emerged. 
Oncocytomas are defined as neoplasms consisting of 
cells with an abundant amount of eosinophilic granu-
lar cytoplasm packed with swollen mitochondria and 
composed solely or mostly of oncocytes [5]. 
They are mostly localised in the adrenal cortex; 
rarely they have been detected in adrenal medulla or 
heterotopic adrenal tissue [6, 7]. Neither environmental 
nor genetic risk factors were found so far for oncocyto-
mas and they are usually incidentally detected [8]. Al-
though the exact incidence is unknown, approximately 
159 cases have been reported in the literature up to 
now [7]. Most of the literature on adrenal oncocytomas 
(AOs) focus on the clinical and pathologic features, 
and a limited number of them reveal the radiological 
findings. In this study, we aimed to present clinical, 
radiological, pathological, and immunohistochemical 
staining features of 11 AOs and review the literature. 
Material and methods
Study population
The study was approved by the Clinical Investiga-
tions Ethics Committee of Uludag University, Faculty 
of Medicine (Reference no: 2013-13/22). The patients 
who were followed up due to adrenal masses in in-
ternal medicine and endocrinology and metabolism 
outpatient clinics of Uludag University Medical Faculty 
between January 2005 and November 2016 were evalu-
ated retrospectively. The inclusion criteria were age 
over 18 years, histopathological diagnosis of AOs after 
surgical resection, available data regarding hormonal 
assessment, and absence of any other malignancy.
Study parameters
Demographic and clinical data such as age, gender, 
signs and symptoms suggesting hormonal activity, 
and accompanying diseases including diabetes mel-
litus (DM), hypertension (HT), coronary artery disease 
(CAD), osteoporosis (OP), thyroid nodule, or hyper-
parathyroidism were recorded. Imaging characteristics 
such as localisation, size, adenomatoid component, 
presence of calcification, and hyperplasia were assessed 
using computerised tomography (CT) or magnetic reso-
nance imaging (MRI). Lin-Weiss-Bisceglia criteria were 
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diseases. However, one patient underwent imaging 
due to left-sided abdominal palpable mass, and one 
patient was evaluated due to characteristic features of 
Cushing syndrome. Five (45.5%) of the masses proved 
to be functional tumours and were more common in 
women. Clinical characteristics and hormonal evalua-
tion of the patients are shown in Table I. 
Five patients had CT and six had MR imaging of the 
abdomen. The masses were 25–130 (57.63 ± 34.04) mm 
in width and 20–100 (47.82 ± 28.95) mm in length. One 
patient had undergone right adrenalectomy in another 
health facility and benign AO had been diagnosed in 
2009. He was admitted to our institution with recurrent 
mass on the left side. Therefore, this mass was consid-
Table I. Clinical characteristics of the patients and hormonal status of the masses
Tabela I. Charakterystyka kliniczna chorych i status hormonalny guzów
Case Age Sex Reason for applying Accompanying illnesses Diagnosis based on hormonal activity
Case 1 31 Female Weight gain, hirsutism, purple 
striae, buffalo hump, moon face
HT + MNG Cushing
Case 2 32 Male Secondary HT workup HT Conn
Case 3 35 Male Abdominal pain None Non-functional
Case 4 35 Female Abdominal pain None Subclinical Cushing
Case 5 39 Male Shortness of breath Chronic bronchitis Non-functional
Case 6 39 Female Palpable mass None Non-functional
Case 7 50 Male Intermittent urination None Non-functional
Case 8 52 Male Side pain None Non-functional
Case 9 54 Female Weight gain DM2, HT, OP Cushing
Case 10 56 Female Abdominal pain HT Non-functional
Case 11 76 Female Secondary HT workup HT Conn
HT — hypertension; MNG — multinodular goitre; DM2 — diabetes mellitus type 2; OP — osteoporosis
Table II. Radiological characteristics of oncocytomas 
Tabela II. Charakterystyka radiologiczna nowotworów onkocytarnych
Case Imaging 
method
Side Mass size Radiological characteristics
Case 1 CT Left 30 × 25 mm Densely stained, ovoid, homogeneous solid lesion with regular margins (HU: 7)
Case 2 MRI Left 62 × 56 mm Lesion with regular margins, isointense to liver, significant signal drop-off on out-of-
phase images due to the high lipid content 
Case 3 MRI Right 72 × 69 mm Lesion containing cystic foci with the biggest one being approximately 1 cm, absence of 
signal drop-off on out-of-phase images due to the poor lipid content 
Case 4 CT Right 35 × 35 mm Solid lesion containing millimetric calcification 
Case 5 MRI Left 108 × 96 mm Lesion with solid appearance, containing small cystic components from place to place, 
heterogeneous enhancement after contrast administration, absence of signal drop-off on 
out-of-phase images due to the poor lipid content 
Case 6 CT Left 130 × 100 mm Lesion containing necrotic areas (HU: 43)
Case 7 MRI Left 50 × 30 mm Ovoid non-adenomatous lesion containing cystic and necrotic areas, absence of signal 
drop-off on out-of-phase images due to the poor lipid content 
Case 8 CT Bilateral 46 × 43 mm Two lesions compatible with non-adenoma (HU: 29)
Case 9 MRI Right 50 × 32 mm Non-adenomatous lesion, absence of signal drop-off on out-of-phase images due to the 
poor lipid content 
Case 10 MRI Right 25 × 20 mm Non-adenomatous lesion, absence of signal drop-off on out-of-phase images due to the 
poor lipid content 
Case 11 CT Right 26 × 20 mm Round lesion with regular contours with a relative contrast wash-out 56% 
CT — computed tomography; MRI — magnetic resonance, HU — Hounsfield units
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ered to be bilateral. The radiological characteristics of 
the masses are shown in Table II.
The pathological and immuno-histochemical fea-
tures are shown in Table 3. Immuno-histochemical 
profile was studied in five cases. Chromogranin A was 
negative and Melan-A was positive in all cases. The 
duration of follow-up was 6–82 months after surgery 
(mean 29.7 months) (Table III). 
Discussion
Oncocytomas commonly occur in kidney, thyroid, 
parathyroid, salivary, and pituitary gland. They rarely 
originate from respiratory system, larynx, and cho-
roid plexus [8]. Oncocytomas of adrenal glands are 
extremely rare.
It has been reported to occur at any age without a cer-
tain age distribution (mean age at diagnosis is 47 years, 
ranging from 27 to 72 years) [8]. Also, there are case reports 
in childhood [10]. Our patients were aged between 31 and 
76 years (45.36 ± 13.68), compatible with the literature. 
AOs have a female preponderance with a ratio of 2.5:1 in 
the literature [8]. We did not observe a prominent gender 
preponderance (1.19:1) in concordance with the report 
(1.8:1) by Wong et al. [11]. Nearly half of our patients had 
HT (n = 5). Two had hyperaldosteronism and two had 
Cushing syndrome, which may contribute to HT. Only 
one had non-functional AO. The patient with subclinical 
Cushing syndrome also did not have HT. These findings 
suggest a close relation between overt hormone secretion 
and HT in cases with AOs. On the other hand, another 
comorbidity accompanying functional adrenal tumours 
is DM, which was rarely encountered in our series (only 
one patient with Cushing syndrome). 
AOs are mostly detected incidentally and 17% of 
them have been reported to be hormonally active 
[8]. Since the first description of AOs by Kakimoto 
et al., 49 hormone-secreting cases were published in 
the literature [12]. AOs secreting androgen, cortisol, 
and aldosterone together or individually have been 
reported. Also, there are case reports regarding inter-
leukin-6 producing AOs [13]. It has been shown that 
patients may present with pseudo-precocious puberty 
and virilisation due to the androgen hypersecretion [8, 
14]. Another clinical presentation is Cushing syndrome, 
and approximately 6 cases were published in the litera-
ture [12]. In our study, two patients were diagnosed 
with Cushing syndrome, and only one of them had 
typical Cushing stigmata. To the best of our knowl-
edge, there is only one case report presenting with 
subclinical Cushing syndrome associated with AO. 
One of our patients had subclinical Cushing syndrome 
[15]. Although very rare, aldosterone-secreting AOs 
have also been reported [16]. Two of our patients were 
diagnosed with hyperaldosteronism during workup 
for secondary hypertension. Five masses (45.5%) were 
found to be functional, similarly to past studies but 
in line with the data from a study done by Wong et 
al., which reported the hormonal activity as 54% [11]. 
These findings suggest that AOs exert endocrinological 
activity more than previously thought.
AOs have a predilection for the left side, with a ratio 
of 2–3.5:1 [3, 17]. We did not detect a predilection for 
localisation. AOs were generally large in size. The size 
of the masses ranged from 30 to 150 mm with a mean 
of 80 mm [18, 19]. In our study the dimensions for 
width and length were (25–130 mm, 57.63 ± 34.04 mm 
and 20–100 mm, 47.82 ± 28.95 mm, respectively) 
Table III. Pathological diagnoses, immunohistochemical examination, and follow-up periods of the patients
Tabela III. Diagnoza histopatologiczna, badanie immunohistochemiczne i okresy obserwacji chorych
Case Pathological diagnosis Immunohistochemical examination Follow-up period
Case 1 Benign Not examined 19 months
Case 2 Uncertain malignant potential Synaptophysin (negative) Inhibin (weakly positive) 15 months
Case 3 Benign Not examined 27 months
Case 4 Benign Synaptophysin (weakly positive) Inhibin (positive) 19 months
Case 5 Uncertain malignant potential Synaptophysin (negative) Inhibin (negative) 32 months
Case 6 Uncertain malignant potential Synaptophysin (negative) Inhibin (positive) 24 months
Case 7 Benign Not examined 6 months
Case 8 Uncertain malignant potential Synaptophysin (positive) 
Inhibin (positive)
82 months
Case 9 Benign Not examined 60 months
Case 10 Benign Not examined 25 months
Case 11 Benign Not examined 18 months
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similar to previous reports. In one of the largest stud-
ies regarding the imaging characteristics of AOs, the 
mean diameter of benign oncocytic tumours was 
76 mm, and the authors suggested that size criteria 
used for adrenal adenomas are not reliable for benign 
AOs [20]. While radiological characteristics for renal 
oncocytomas are well defined, there is no imaging 
characteristic for AOs. Central scarring at varying rates 
can be observed on CT or MR images; however, it is 
not a reliable indicator of differentiating benign AOs 
from malignant ones and oncocytomas from other 
adrenal masses [7, 8, 20]. We observed some imaging 
characteristics compatible with pheochromocytomas 
and adrenocortical carcinomas.
AOs and other adrenal masses are treated in the 
same way, taking functional status and radiological 
characteristics into consideration for surgery. All of 
the AO cases in the literature have been diagnosed 
retrospectively because there are no definite clinical 
or radiological features to discriminate preoperatively.
According to the current classification system, AOs 
are divided into three histological categories: benign, 
uncertain malignant potential, and malignant. The 
histological scoring system for adrenocortical tumours 
was first introduced by Weiss [21]. Recently, Bisceglia 
et al. recommended a scoring system consisting of 
major and minor criteria, especially to determine the 
histological extent of the AOs [9]. Three major criteria 
are high mitotic rate (> 5 mitosis in 50× magnification), 
atypical mitosis, and venous invasion. Four minor crite-
ria include tumour measuring over 10 cm in diameter 
or weighing over 200 g, tumour necrosis, and capsular 
and sinusoidal invasion. The presence of one major 
criteria confirms malignancy, 1–4 minor criteria indicate 
uncertain malignant potential, and absence of major 
and minor criteria suggest benignity [9]. Seven of 11 
patients were classified as benign and the remaining 
as uncertain malignant potential (63.6% and 36.4%, re-
spectively), according to the Lin-Weiss-Bisceglia criteria 
in our study. In a review of the pathologic features of 
147 cases, approximately 80% of cases were reported to 
have benign or low malignancy potential [8]. To the best 
of our knowledge, there were 47 cases with uncertain 
malignant potential in the literature [11]. 
Determining the immunohistochemical profile of 
AOs is difficult because immunohistochemical exami-
nation was not performed and same staining pattern 
was not used in all cases. In challenging situations, im-
munohistochemical examinations aid in differentiating 
adrenocortical tumours from the medullary ones. They 
are generally negative for S100 and chromogranin and 
positive for melan-A [8, 22, 23]. Inhibin is generally 
positive [8, 11, 23, 24]. Low positivity rate has been 
reported for synaptophysin [8, 11, 22]. Although im-
munoreactivity for vimentin is variable, diffuse posi-
tivity is evident in most cases [8, 11, 14, 22, 24]. Sangoi 
and McKenney compared 63 adrenocortical lesions 
with 35 pheochromocytomas using the usual stains 
(chromogranin, calretinin, inhibin, melan A, and syn-
aptophysin) and novel (steroidogenic factor-1 [SF-1], 
microtubule-associated protein 2, and mammalian 
achaete-scute homolog-1) antibodies. The adrenocor-
tical tumours were 100% negative for chromogranin, 
89% positive for calretinin, 86% positive for inhibin 
and melan-A, and 59% positive for synaptophysin. The 
authors concluded that chromogranin plus SF-1, cal-
retinin, or inhibin improves diagnostic sensitivity and 
specificity [25]. In our study chromogranin-negative 
and melan-A-positive staining in all specimens support 
the previous reports. 
Prognosis of AOs varies according to the histological 
subtype. Currently, there are no recommendations for 
follow-up of benign AOs. The follow-up duration rang-
es from six months to 37 months without any recurrence 
in current literature [17, 26]. There was only one case 
which was initially reported as benign but diagnosed to 
be malignant AO after recurrence and re-examination of 
the original specimen [9]. We did not observe recurrence 
of disease during 6–60 (mean 24.8) months of follow-up 
in seven patients with benign AOs. Recurrence rates for 
AOs with uncertain malignant potential are variable. 
It was reported as 6% in a series of 47 patients during 
a mean follow-up of 96 months [11]. Bisceglia et al. 
reported no recurrence in four patients during a mean 
follow-up time of 38.7 (10–61) months [9]. Lin et al. also 
did not observe recurrence in two patients followed up 
for 12–19 (mean 15.5) months [22]. We followed up four 
patients with uncertain malignant potential for 15–82 
(mean 38.25) months, similarly to the study by Bisceglia 
et al. [9]. Wong et al. showed that estimated total median 
survival period of malignant AOs was 58 months (95% 
confidence interval 27.5–88.5 months), which was better 
than that of adrenocortical carcinomas [11]. We have no 
experience with malignant AOs.
Conclusions
AOs pose challenges during radiological and histologi-
cal examinations. They usually occur in adults. They 
are frequently non-functional; however, half of them 
may present as hormone active tumours, as we have 
shown. CT or MRI features cannot conclusively dif-
ferentiate AOs from other adrenal masses or benign 
AOS from malignant ones. We observed that AOs 
may reveal imaging features common with pheo-
chromocytomas and adrenocortical carcinomas. They 
are usually benign, although those with uncertain 
malignant potential or malignancy may be evident. 
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Therefore, because there is no clear evidence regarding 
the true potential of this tumour, long-term follow-up 
is recommended.
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